ライフサイエンスコーパス: breakthrough infection

1 CoV-2 infection after vaccination (so-called breakthrough infection).

2 -CoV-2-specific antibody response had a mild breakthrough infection.

3 d increase and 3.1-fold decrease for Omicron breakthrough infection.

4 lter booster administration in response to a breakthrough infection.

5 neutralizing-antibody response after Omicron breakthrough infection.

6 vaccination, natural protection, and vaccine breakthrough infection.

7 including vaccination, primary infection and breakthrough infection.

8 nity is the most likely explanation for this breakthrough infection.

9 s following vaccination and possible risk of breakthrough infection.

10 was seen only among HTx recipients with CMV breakthrough infection.

11 eviously, we identified 2 women with vaccine breakthrough infection.

12 atly reduced in fully vaccinated people with breakthrough infection.

13 vely in vaccinees who experienced SARS-CoV-2 breakthrough infection.

14 er diagnosis, and 39 109 (14.8%) developed a breakthrough infection.

15 doses of mRNA vaccine with or without alpha breakthrough infection.

16 of 5.9 months, 68 (2.5%) participants had a breakthrough infection.

17 sed to low-level replication as the cause of breakthrough infection.

18 .16; 95% CI, 1.96-2.38) had a higher rate of breakthrough infection.

19 RS-CoV-2-specific antibodies and experienced breakthrough infection.

20 an efficacious HIV/AIDS vaccine, even after breakthrough infection.

21 was seen only among HTx recipients with CMV breakthrough infection.

22 immune responses in vaccinated hosts during breakthrough infection.

23 will be crucial to identify the mechanism of breakthrough infections.

24 -CoV and WIV-1 challenge in mice resulted in breakthrough infections.

25 ferring varying levels of protection against breakthrough infections.

26 hallenge with a higher dose, however, led to breakthrough infections.

27 dented transmissibility and ability to cause breakthrough infections.

28 iants of concern have emerged that can cause breakthrough infections.

29 S-CoV-2 are needed to anticipate the risk of breakthrough infections.

30 2 variants, may account for reinfections and breakthrough infections.

31 f multiple innate immune cell subsets during breakthrough infections.

32 June 2021, of which 125 (9.1%) were vaccine breakthrough infections.

33 kthrough infections, and mRNA-1273 (Moderna) breakthrough infections.

34 tant and thus more likely to lead to vaccine breakthrough infections.

35 pose to higher acute viremia in the event of breakthrough infections.

36 n, similar to results with 2022 CP from BA.1 breakthrough infections.

37 COVID-19 vaccine-induced seropositivity and breakthrough infections.

38 ffectiveness of two-dose vaccination against breakthrough infections.

39 cluding for most patients who had SARS-CoV-2 breakthrough infections.

40 ur results may help to improve prediction of breakthrough infections.

41 a combination of widespread vaccination and breakthrough infections.

42 ralizing antibody titers, suggesting ongoing breakthrough infections.

43 bly explaining suppressed viremia in vaccine breakthrough infections.

44 cination were at markedly decreased risk for breakthrough infections.

45 uced immune responses and protection against breakthrough infections.

46 ults in improved early disease parameters in breakthrough infections.

47 well as durably control viral replication in breakthrough infections.

48 y of the gamma -spz could explain occasional breakthrough infections.

49 alysed; only three were classified as "true" breakthrough infections.

50 -2.06) across the range of uncertainty about breakthrough infections.

51 t who cannot be vaccinated or who experience breakthrough infections.

52 .88]) were associated with increased risk of breakthrough infections.

53 generally higher than those against BA.1 in breakthrough infections.

54 humans to antibody-dependent enhanced (ADE) breakthrough infections?

55 Of the 1700 breakthrough infections, 1665 reported on severity; 112

56 ed in all ages and were marginally lower for breakthrough infections, 2.33 (95% CI [1.96, 2.76]; p <

57 Among 248 fully vaccinated patients with breakthrough infections, 203 (82%) were symptomatic and

58 similar total anti-FLS IgG levels following breakthrough infection, 4-fold higher plasma concentrati

59 a higher proportion of asymptomatic or mild breakthrough infections (55.0% versus 28.6%, respectivel

60 Most breakthrough infections (57/76) occurred with B.1.1.7 (A

61 Serological breakthrough infection (7106 mIU/mL) was documented in 1

62 r thrice vaccinated individuals with omicron breakthrough infection; a 46-fold increase in plasma neu

63 Interestingly, in the RMs showing breakthrough infections, AdC7/6-SIV immunization was ass

64 n was associated with a 28% reduced risk for breakthrough infection (adjusted IRR [AIRR], 0.72; 95% C

65 ogic malignancies were at increased risk for breakthrough infections (adjusted OR ranged from 2.07 fo

66 However, a single mouse experienced breakthrough infection after 63 days when the serum HMAb

67 ction IgG levels in the 40 participants with breakthrough infection after dose 2 were similar to leve

68 People with a breakthrough infection after full vaccination were more

69 ased awakening frequency was associated with breakthrough infection after the 1st booster with 3.01 +

70 ratio 1.17, P = 0.019) were associated with breakthrough infection after the 1st booster.

71 256 out of 5265 individuals reported a breakthrough infection after the 2nd vaccine, and 581 ou

72 BNT162b2 COVID-19 vaccine had a low risk of breakthrough infection after up to 8 months of follow-up

73 ciated with an increased risk for SARS-CoV-2 breakthrough infection after vaccination, but no studies

74 A total of 1 080 348 vaccine-breakthrough infections after an ancestral mRNA booster

75 reduction in risk of all-cause mortality for breakthrough infection among CLD patients with cirrhosis

76 a statistically significantly lower risk for breakthrough infection among individuals receiving the B

77 ociation of BA.4/BA.5 with increased risk of breakthrough infection among previously vaccinated or in

78 avirus 2 (SARS-CoV-2) Omicron variant causes breakthrough infections among convalescent patients and

79 immune responses, and the high incidence of breakthrough infections among vaccinated individuals hig

80 red in 13 patients (4%), including 1 case of breakthrough infection and 12 relapses, and was associat

81 Odds of SARS-CoV-2 breakthrough infection and COVID-19 hospitalization.

82 Endpoints included COVID-19 breakthrough infection and COVID-19-associated emergency

83 the success of Omicron subvariants to cause breakthrough infection and reinfection may in part be du

84 Risks for breakthrough infection and severe outcomes were analyzed

85 mune suppression had a higher risk of severe breakthrough infection and should be included in groups

86 memory T cell populations occurs early after breakthrough infection and suggests that CD8(+) T cells

87 NT162b2 vaccine, examining their relation to breakthrough infections and immune imprinting in the con

88 ignancies, are at higher risk for developing breakthrough infections and severe outcomes.

89 Increases in N IgG identified vaccine breakthrough infections and showed >15% breakthrough inf

90 acute seronegative HIV infection and in PrEP breakthrough infections and that FTC is associated with

91 l lenacapavir resistance given the rarity of breakthrough infections and the reduced replication capa

92 inst emerging variants and the prevention of breakthrough infections and transmission remain elusive.

93 Johnson & Johnson's Ad26.CoV2.S and had BA.1 breakthrough infections, and 24 were unvaccinated.

94 2799 (69%) were unvaccinated, 475 (12%) were breakthrough infections, and 782 (19%) had unknown vacci

95 ns, reinfections, BNT162b2 (Pfizer-BioNTech) breakthrough infections, and mRNA-1273 (Moderna) breakth

96 Outcomes among persons with breakthrough infection are poorly understood.

97 ing immunity from infection and vaccination, breakthrough infections are becoming increasingly common

98 Breakthrough infections are common, even in highly vacci

99 ections, variant viruses continue to emerge, breakthrough infections are frequent, and vaccine hesita

100 is connected to people who are unvaccinated, breakthrough infections are increasingly frequent for in

101 It is unknown if vaccine breakthrough infections are milder or as severe as infec

102 n in the United States are highly effective, breakthrough infections are occurring.

103 accinated, and fully vaccinated individuals (breakthrough infections) as well as reinfections.

104 However, its impact on the risk of breakthrough infection (BI) has yet to be assessed.

105 spective contributions to protection against breakthrough infections (BIs) after vaccination.

106 r was associated with increased incidence of breakthrough infection, both in models adjusted for pote

107 oV-2 variants and whether vaccination and/or breakthrough infection (BTI) can elicit antibodies capab

108 Associations among breakthrough infection (BTI), vaccine responses, and pat

109 V-2 Delta variant was weakly associated with breakthrough infection, but several potential nonlineage

110 gest medical center in Israel, we identified breakthrough infections by performing extensive evaluati

111 High rates of breakthrough infections by the Omicron variant emphasize

112 duals and the later clinical consequences of breakthrough infection can provide insight into strategi

113 Until uncertainty about breakthrough infections can be addressed empirically, ou

114 , we identified 1728 vaccinated persons with breakthrough infection (cases) and 1728 propensity score

115 dds (95% confidence interval 1.45-1.85) of a breakthrough infection compared to BNT162b2.

116 piratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection compared to controls.

117 show higher mean Ct value in all cohorts of breakthrough infections compared to the cohort of primar

118 he 150-150 mg dose had a higher incidence of breakthrough infections compared to those who received t

119 PWH had an increased risk of breakthrough infections compared with PWoH.

120 d evasion of humoral immunity from BA.1/BA.2 breakthrough-infection convalescent plasma but greater e

121 alescent plasma but greater evasion of Delta breakthrough-infection convalescent plasma.

122 low-frequency alleles) were associated with breakthrough infection, defined as SARS-CoV-2 infection

123 COVID-19 breakthrough infections, defined as laboratory evidence

124 Patients with cancer who develop breakthrough infection despite full vaccination, however

125 and duration of illness among those who had breakthrough infection despite vaccination.

126 Our findings suggest that breakthrough infections diversify the T cell memory repe

127 were less likely to experience PCR-confirmed breakthrough infection during the ancestral SARS-CoV-2 v

128 wer among participants who later experienced breakthrough infection during the Delta surge (median, 2

129 h lower antibody levels were associated with breakthrough infection during the Delta surge, no signif

130 5% CI, 3.7-11.1) compared with those without breakthrough infection during the Omicron surge (median,

131 Omicron breakthrough infections elicited high levels of cross-re

132 Breakthrough infection elicits minimal de novo Omicron B

133 ination followed by viral infection, such as breakthrough infection, eosinophils have been linked to

134 Patients with SARS-CoV-2 breakthrough infections exhibit cellular immune response

135 Importantly, sera from people who had XBB breakthrough infection exhibited robust neutralizing act

136 ctories after a third/booster vaccination or breakthrough infection following second vaccination in 1

137 booster were contrasted against 9824 vaccine-breakthrough infections following a bivalent mRNA booste

138 x, and previous infection, hazard ratios for breakthrough infection for having twice the immunologica

139 cinated hosts, key features that distinguish breakthrough infection from both Type 1- and Type 2-skew

140 Breakthrough infections generated similar antibody level

141 methods and tools applicable to analysis of breakthrough infection genomes in general vaccine effica

142 continued gel dosing postinfection, neither breakthrough infection had evidence of drug resistance b

143 accinated patients, vaccinated patients with breakthrough infections had a higher percentage of antig

144 vaccinated patients with confirmed COVID-19 breakthrough infections had lower rates of true-positive

145 High proportions of breakthrough infection have been observed.

146 However, waning immunity and breakthrough infections have been observed.

147 ry syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough infections have been reported, including in

148 lution of new variants and the occurrence of breakthrough infections highlight the need for new and e

149 COVID-19 breakthrough infections, hospitalisations, and deaths we

150 In breakthrough infections, hospitalization rate was simila

151 nfections, vs 6.7% and 1.3% in those without breakthrough infections (HR for hospitalization: 13.48;

152 ion against infection, leaving the extent of breakthrough infections (i.e., disease ameliorated but i

153 y towards vaccines and common occurrence of "breakthrough" infections (i.e., infections of vaccinated

154 ) and infection-blocking admitting only mild breakthrough infections (IB_MB).

155 host are consistent with clinical reports on breakthrough infection in anti-HBs-positive patients inf

156 ntibody titers increased up to 28 days after breakthrough infection in both groups.

157 trends, outcomes and disparities of COVID-19 breakthrough infection in fully vaccinated SUD patients

158 unted serologic reactivity; investigation of breakthrough infection in PrEP users; and potentially fo

159 nses up to six months following Omicron BA.1 breakthrough infection in six mRNA-vaccinated individual

160 Breakthrough infection in the 72-h group was detected at

161 Breakthrough infections in both cohorts were associated

162 Breakthrough infections in immunized subjects seem to as

163 Breakthrough infections in patients with cancer were ass

164 S-CoV-2 vaccine-induced immune responses and breakthrough infections in patients with inflammatory bo

165 or vaccination to monitor formerly unnoticed breakthrough infections in the population as well as to

166 of the first complete-genome analysis of the breakthrough infections in the RV144 trial, this work de

167 unvaccinated persons, there were 2332 (0.5%) breakthrough infections in the vaccinated group and 40 5

168 (HCWs) in Israel, a high rate of SARS-CoV-2 breakthrough infections in this group was observed durin

169 Concerns have been raised that omicron breakthrough infections in triple-vaccinated individuals

170 Breakthrough infections in vaccinated, healthy persons c

171 s the importance of comprehensive studies of breakthrough infections in vaccine trials to determine w

172 Breakthrough infection incidences were 5.4 and 4.9 per 1

173 Although breakthrough infection increased risk of death, vaccinat

174 Breakthrough infections increased antibodies to similar

175 Despite Omicron breakthrough infection increasing IgG and IgA against FL

176 examine if sleep metrics predicted COVID-19 breakthrough infection independent of age and gender.

177 By contrast, Omicron breakthrough infections induce overall higher neutraliza

178 Here, we demonstrate that breakthrough infections induce serum-binding and -neutra

179 g immunocompetent, unboosted patients, Delta breakthrough infections induced 10.8-fold higher titers

180 investigated through sieve analysis of HIV-1 breakthrough infections (infected vaccine and placebo re

181 at eosinophilic recruitment during influenza breakthrough infection is non-pathological and represent

182 Measurement of breakthrough infections is challenging outside of random

183 etroviral resistance selected by PrEP during breakthrough infections is important because of the risk

184 Prior vaccination followed by Delta or BA.1 breakthrough infections led to a high degree of cross-re

185 Following either Delta or Omicron breakthrough infection, limited variant-specific cross-n

186 In subjects with SARS-CoV-2 breakthrough infections, local virus-specific B(RM) cell

187 mmunity against SARS-CoV-2 following Omicron breakthrough infection manifests significantly less ADCC

188 The results suggest that 6 of 7 breakthrough infections may be related to incomplete imm

189 yield lower, shorter-term protection against breakthrough infection (median 22.4 mo and 5 to 95% quan

190 95% CI, 1.8-2.9) compared with those without breakthrough infection (median, 5.8; 95% CI, 5.5-6.1) (P

191 ically yield more durable protection against breakthrough infections (median 29.6 mo; 5 to 95% quanti

192 e we studied six AMP trial participants with breakthrough infections mediated by multiple viral linea

193 Breakthrough infection mice exhibit lung eosinophil infi

194 utrophil extracellular traps in the lungs of breakthrough infection mice, in contrast with allergic s

195 In contrast, individuals after breakthrough infection mount vigorous non-spike-specific

196 orbid conditions, and those with vaccination breakthrough infections must be interpreted in the conte

197 going uncertainties about virus variants and breakthrough infections necessitate continued vigilance

198 In 22 KTRs with Omicron variant breakthrough infections, neutralizing antibody activity

199 Although multiple vaccines are available, breakthrough infections occur especially by emerging var

200 Although breakthrough infections occur in partially protected vac

201 high-risk hematological disorders; however, breakthrough infections occur, and the reasons for treat

202 (SARS-CoV-2) vaccines report >90% efficacy, breakthrough infections occur.

203 nsights into the potential mechanisms behind breakthrough infections occurred even after the vaccinat

204 Breakthrough infections occurred in >40% of participants

205 Breakthrough infections occurred more frequently among p

206 ce indexes was observed in participants with breakthrough infections occurring after specimen collect

207 nse were at much greater risk for SARS-CoV-2 breakthrough infection (odds ratio [OR], 3.05; 95% CI, 1

208 ry to ensure persistent immunity to minimize breakthrough infections of COVID-19, due to newly emergi

209 Breakthrough infections of severe acute respiratory synd

210 Rising breakthrough infections of severe acute respiratory synd

211 -19, but little is known about the impact of breakthrough infections on memory responses.

212 variant-specific epitopes induced following breakthrough infection or bivalent vaccination can bridg

213 ation monitoring may be required to minimize breakthrough infection or relapsing mucormycosis associa

214 ata suggest that two vaccine doses and delta breakthrough infection or three vaccine doses and option

215 "True" breakthrough infections (or PEP failures) were defined a

216 ived a booster vaccination, recovered from a breakthrough infection, or both.

217 otherapy (aOR, 2.71; CI, 2.27-3.24) prior to breakthrough infection, or leukemias or lymphomas (aOR,

218 increased hospitalization and mortality from breakthrough infections, our findings have implications

219 durability of immunity and the likelihood of breakthrough infections over time following vaccination

220 er and frail males may be more vulnerable to breakthrough infections owing to low antibody responses

221 BA.5 breakthrough-infection plasma also exhibits weaker neutr

222 spite high vaccine coverage with evidence of breakthrough infections, posing significant challenges t

223 Whereas none of the 16 breakthrough infections possessed vaccine-induced HIV-1-

224 In patients with breakthrough infection prior to the fourth dose (n = 27)

225 cine type (OR, 0.72; 95% CI, .51-.99), while breakthrough infection prior to the fourth dose (OR, 3.6

226 SARS-CoV-2 vaccination, whether boosters or breakthrough infections provide greater protection again

227 Among SUD patients, the risk for breakthrough infection ranged from 6.8% for tobacco use

228 BNT162b2 vaccine dose resulted in a reduced breakthrough infection rate among hospital staff.

229 ys, which could account for the high vaccine breakthrough infection rates and limited duration of vac

230 cine breakthrough infections and showed >15% breakthrough infection rates during the Omicron wave sta

231 Overall breakthrough infection rates were 368 of 5331 (7%) in th

232 In this N3C study, breakthrough infection rates were similar among CLD pati

233 d sleep around COVID-19 vaccination affected breakthrough infection rates.

234 Decreased antibody responses in Omicron breakthrough infections relative to Delta were potential

235 Increased rates of breakthrough infection, renal scarring and surgical fail

236 riable predictors of breakthrough and severe breakthrough infection, respectively.

237 Both Delta and BA.1 breakthrough infections resulted in strong nAb responses

238 antify the extent to which uncertainty about breakthrough infections results in uncertainty about vac

239 Moreover, sequencing of viruses from breakthrough infections revealed selective pressure agai

240 Breakthrough infection risk remained significantly highe

241 Breakthrough infection risk was 28% higher in PWH vs PWo

242 ination dose: primary outcome was SARS-CoV-2 breakthrough infection; secondary outcomes were emergenc

243 Interestingly, RMs experiencing breakthrough infection showed significantly higher prech

244 Breakthrough infections showed similar risk of psychiatr

245 dentified 10 genomic regions associated with breakthrough infection (SLC6A20, ST6GAL1, MUC16, FUT6, M

246 ion from severe disease and hospitalization, breakthrough infections still occur, most likely due to

247 n had substantially higher risk for COVID-19 breakthrough infection than those without such a conditi

248 cer within the past year had higher risk for breakthrough infections than those who did not (HR, 1.24

249 the COVID-19 pandemic, most infections are "breakthrough" infections that occur in individuals with

250 rthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significan

251 Following Delta breakthrough infection, titers against WT rose 57-fold a

252 a symptomatic fully vaccinated patient with breakthrough infection to household contacts was suspect

253 Breakthrough infections underline the importance of earl

254 vaccines and subsequently increased risk for breakthrough infections, underscoring the need for addit

255 Breakthrough infections, usually after incomplete RV vac

256 Among breakthrough infections, vaccinated patients demonstrate

257 respiratory syndrome coronavirus 2 "vaccine-breakthrough" infections (VBIs).

258 cancer had significantly increased risk for breakthrough infections vs patients without cancer (HR,

259 .6% and 3.9%, respectively, in patients with breakthrough infections, vs 6.7% and 1.3% in those witho

260 New SARS-CoV-2 variants, breakthrough infections, waning immunity, and sub-optima

261 Breakthrough infection was 4-25 times more common during

262 Overall, the incidence rate for COVID-19 breakthrough infection was 5.0 per 1000 person-months am

263 Breakthrough infection was defined as a COVID-19 infecti

264 -19 breakthrough illness within 28 days of a breakthrough infection was low among vaccinated PWH and

265 Higher burden of severe breakthrough infections was identified in subgroups.

266 Correlates of breakthrough infection were assessed in a case-control a

267 icant age, gender and ethnic disparities for breakthrough infection were observed in vaccinated SUD p

268 tection against Omicron BA.4/5 infection and breakthrough infections were associated with higher leve

269 Breakthrough infections were characterised clinically an

270 Breakthrough infections were characterized by a less act

271 Asymptomatic breakthrough infections were detected in 16 participants

272 ved between the two vaccines, although fewer breakthrough infections were detected in the BA.5-vaccin

273 type and BA.5 vaccine-boosted animals, fewer breakthrough infections were detected in the BA.5-vaccin

274 om RT-PCR data were available, 39 SARS-CoV-2 breakthrough infections were documented.

275 A small proportion of breakthrough infections were due to PVF than SVF.

276 Antibody level trajectories and frequency of breakthrough infections were evaluated by tumor type and

277 es available for serologic analyses, vaccine breakthrough infections were found to be associated with

278 e followed up through 14 months, and vaccine breakthrough infections were identified by increasing le

279 Most breakthrough infections were mild or asymptomatic, altho

280 Breakthrough infections were mostly mild, and hospitaliz

281 ccine no longer offered good protection, and breakthrough infections were observed in all animals and

282 on of Wuhan-Hu-1 persisted following Omicron breakthrough infection, which increased IgG avidity agai

283 larpGAP was completely attenuated showing no breakthrough infections while efficiently inducing high-

284 ose with COVID-19 before vaccination or with breakthrough infections who had blood samples and sympto

285 mia while receiving ganciclovir; 3 (20%) had breakthrough infection with all three methods, including

286 Longitudinal comparison of breakthrough infection with allergic sensitization and p

287 tudy, rhesus macaques, after vaccination and breakthrough infection with homologous simian-human immu

288 days of follow-up (adjusted hazard ratio for breakthrough infection with prior infection, 0.18 [95% C

289 39%) of 36 volunteers subsequently developed breakthrough infection with the omicron variant after di

290 No increase in breakthrough infections with antibiotic-resistant organi

291 n status was known, a substantial number had breakthrough infections with Delta or Omicron variants (

292 However, breakthrough infections with fungal pathogen Aspergillus

293 Breakthrough infections with SARS-CoV-2 Delta variant ha

294 nated health care workers, the occurrence of breakthrough infections with SARS-CoV-2 was correlated w

295 Breakthrough infections with severe acute respiratory sy

296 Breakthrough infections with severe acute respiratory sy

297 ID-19) vaccine antibody response and risk of breakthrough infection, with implications for future vac

298 re associated with an increased incidence of breakthrough infection, with the highest relative risk o

299 Of the KTRs, 16% experienced breakthrough infections, with 2 hospitalizations; prebre

300 Breakthrough infections within 3 months occur despite pa